The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Valneva is committed to upholding the highest safety standards and has engaged proactively with health authorities in all territories where IXCHIQ ® is licensed to provide timely information about all ...

The US Centers for Disease Control and Prevention (CDC) is warning people planning to travel to the Region of the Indian ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

Ixchiq is the first preventive vaccine against the chikungunya virus authorised in Europe and the US. Among the adverse events included the death of adults aged 62 and 89 years. However, the exact ...

Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Read what ...